Skip to main content
Erschienen in: Clinical and Translational Oncology 2/2016

01.02.2016 | Research Article

The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients

verfasst von: T. Powrózek, R. Mlak, P. Krawczyk, I. Homa, M. Ciesielka, P. Kozioł, M. Prendecka, J. Milanowski, T. Małecka-Massalska

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Platinum-based chemotherapy and 3rd generation drugs is still the main treatment option for advanced non-small cell lung cancer (NSCLC) patients without activating EGFR mutations or ALK rearrangements. However, the side effects associated with cytostatics are well known. Changes in the genes (e.g. single nucleotide polymorphisms, SNPs) encoding proteins regulating DNA repair or cell division could potentially influence on both the susceptibility of cancer cells to chemotherapy, and the occurrence of toxicities.

Materials and methods

In presented study, the relationship between the fourteen SNPs in nine DNA repair and cell division regulating genes: ERCC1, XPD, XPA, XPC, XRCC1, XPG, RRM1, BRCA1, STMN1 and the toxicity of first-line chemotherapy in NSCLC patients were investigated. SNPs were determined by SNaPshot PCR® in DNA isolated from peripheral blood of 55 NSCLC patients treated with platinum compound and vinorelbine. The toxicity of therapy was evaluated according to the Common Toxicity Criteria (CTC) Version 4.03.

Results

The odds ratio (OR) of severe haematological toxicity was significantly lower in carriers of the T allele of XRCC1 gene (1196A > G, OR = 0.22, 95 % CI: 0.06–0.82, p  = 0.018) and higher in the carriers of the T allele (2704C > A) of XPC gene (OR: 7.50, 95 % CI: 0.89–63.17, p = 0.036) compared to the remaining patients. Risk of severe hepatotoxicity was significantly lower in carriers of the C allele of STMN1 (−2166T > C, OR = 0.09, 95 % CI: 0.01–1.12, p = 0.025) than in patients with T allele of this gene. In carriers of G allele (2251A > C, OR: 0.24, 95 % CI: 0.07–0.81, p = 0.017) and T (934G > A, OR: 0.26, 95 % CI: 0.07–0.90, p = 0.029) of XPD gene, risk of severe nephrotoxicity was significantly lower than in other patients.

Conclusions

Selected SNPs of genes encoding DNA repair enzymes and cell division regulation proteins could be useful biomarkers for prediction of platinum and vinorelbine-based chemotherapy toxicity in patients with advanced NSCLC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Revannasiddaiah S, Thakur P, Bhardwaj B, Susheela SP, Madabhavi I. Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. J Thorac Dis. 2014;6(Suppl 5):S502–25.PubMedCentralPubMed Revannasiddaiah S, Thakur P, Bhardwaj B, Susheela SP, Madabhavi I. Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. J Thorac Dis. 2014;6(Suppl 5):S502–25.PubMedCentralPubMed
4.
Zurück zum Zitat Stinchcombe TE. Novel agents in development for advanced non-small cell lung cancer. TherAdv Med Oncol. 2014;6(5):240–53.CrossRef Stinchcombe TE. Novel agents in development for advanced non-small cell lung cancer. TherAdv Med Oncol. 2014;6(5):240–53.CrossRef
5.
Zurück zum Zitat NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-small cell lung cancer Version 1.2015 (2014) www.nccn.org. last accessed on 06.Dec 2014. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-small cell lung cancer Version 1.2015 (2014) www.​nccn.​org. last accessed on 06.Dec 2014.
6.
Zurück zum Zitat Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene. 2003;22:3548–53.CrossRefPubMed Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene. 2003;22:3548–53.CrossRefPubMed
7.
Zurück zum Zitat Meng XL, Su D, Wang L, Gao Y, Hu YJ, Yang HJ, et al. Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer. Genet Test Mol Biomarkers. 2012;16:689–94.PubMedCentralCrossRefPubMed Meng XL, Su D, Wang L, Gao Y, Hu YJ, Yang HJ, et al. Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer. Genet Test Mol Biomarkers. 2012;16:689–94.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Zhang L, Gao G, Li X, Ren S, Li A, Xu J, et al. Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS ONE. 2012;7(10):e48350.PubMedCentralCrossRefPubMed Zhang L, Gao G, Li X, Ren S, Li A, Xu J, et al. Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. PLoS ONE. 2012;7(10):e48350.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 2012;118(9):2466–75.CrossRefPubMed Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 2012;118(9):2466–75.CrossRefPubMed
10.
Zurück zum Zitat Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005;11(4):1534–8.CrossRefPubMed Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005;11(4):1534–8.CrossRefPubMed
11.
Zurück zum Zitat Wu W, Zhang W, Qiao R, Chen D, Wang H, Wang Y, et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin Cancer Res. 2009;15(11):3889–95.CrossRefPubMed Wu W, Zhang W, Qiao R, Chen D, Wang H, Wang Y, et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin Cancer Res. 2009;15(11):3889–95.CrossRefPubMed
12.
Zurück zum Zitat Li X, Shao M, Wang S, Zhao X, Chen H, Qian J, et al. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Tumour Biol. 2014;35(11):11159–70.CrossRefPubMed Li X, Shao M, Wang S, Zhao X, Chen H, Qian J, et al. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Tumour Biol. 2014;35(11):11159–70.CrossRefPubMed
13.
Zurück zum Zitat Krawczyk P, Kucharczyk T, Kowalski DM, Powrózek T, Ramlau R, Kalinka-Warzocha E, et al. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J Cancer Res ClinOncol. 2014;140:2047–57.CrossRef Krawczyk P, Kucharczyk T, Kowalski DM, Powrózek T, Ramlau R, Kalinka-Warzocha E, et al. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J Cancer Res ClinOncol. 2014;140:2047–57.CrossRef
14.
Zurück zum Zitat Wang Y, Liu ZD, Zhao LM, Du CX, Xi XM, Mi YL, et al. Individualized treatment of NSCLC: from research to clinical practice. Neoplasma. 2013;60(5):538–45.CrossRefPubMed Wang Y, Liu ZD, Zhao LM, Du CX, Xi XM, Mi YL, et al. Individualized treatment of NSCLC: from research to clinical practice. Neoplasma. 2013;60(5):538–45.CrossRefPubMed
15.
Zurück zum Zitat Zhao H, Zhang H, Du Y, Gu X. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2014. [Epub ahead of print]. Zhao H, Zhang H, Du Y, Gu X. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2014. [Epub ahead of print].
16.
Zurück zum Zitat Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer. 2011;73(2):138–46.CrossRefPubMed Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer. 2011;73(2):138–46.CrossRefPubMed
17.
Zurück zum Zitat Dong J, Hu Z, Shu Y, Pan S, Chen W, Wang Y, et al. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis. MolCarcinog. 2012;51(7):546–52.CrossRef Dong J, Hu Z, Shu Y, Pan S, Chen W, Wang Y, et al. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis. MolCarcinog. 2012;51(7):546–52.CrossRef
18.
Zurück zum Zitat Mazzone P, Mekhail T. Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. Respir Med. 2012;106(4):473–92.CrossRefPubMed Mazzone P, Mekhail T. Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. Respir Med. 2012;106(4):473–92.CrossRefPubMed
19.
Zurück zum Zitat Bowden NA. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Lett. 2014;346(2):163–71.CrossRefPubMed Bowden NA. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Lett. 2014;346(2):163–71.CrossRefPubMed
20.
Zurück zum Zitat Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci. 2009;66(6):981–93.CrossRefPubMed Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci. 2009;66(6):981–93.CrossRefPubMed
21.
Zurück zum Zitat Bonanno L, Favaretto A, Rosell R. Platinum drugs and DNA repair mechanisms in lung cancer. Anticancer Res. 2014;34(1):493–501.PubMed Bonanno L, Favaretto A, Rosell R. Platinum drugs and DNA repair mechanisms in lung cancer. Anticancer Res. 2014;34(1):493–501.PubMed
22.
Zurück zum Zitat Murphy A, Chu JH, Xu M, Carey VJ, Lazarus S, Liu A, et al. Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD4 + lymphocytes. Hum Mol Genet. 2010;19:4745–57.PubMedCentralCrossRefPubMed Murphy A, Chu JH, Xu M, Carey VJ, Lazarus S, Liu A, et al. Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD4 + lymphocytes. Hum Mol Genet. 2010;19:4745–57.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung Pharmacogenomics. 2014;15(12):1565–74.PubMed Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung Pharmacogenomics. 2014;15(12):1565–74.PubMed
24.
Zurück zum Zitat Li Y, Huang XE, Jin GF, Shen HB, Xu L. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. Asian Pac J Cancer Prev. 2011;12(3):739–42.PubMed Li Y, Huang XE, Jin GF, Shen HB, Xu L. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. Asian Pac J Cancer Prev. 2011;12(3):739–42.PubMed
25.
Zurück zum Zitat Sullivan I, Salazar J, Majem M, Pallarés C, Del Río E, Páez D, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 2014;353(2):160–6.CrossRefPubMed Sullivan I, Salazar J, Majem M, Pallarés C, Del Río E, Páez D, et al. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 2014;353(2):160–6.CrossRefPubMed
26.
Zurück zum Zitat Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002;62:6864–9.PubMed Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002;62:6864–9.PubMed
27.
Zurück zum Zitat Balachandran R, Welsh MJ, Day BW. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene. 2003;22:8924–30.CrossRefPubMed Balachandran R, Welsh MJ, Day BW. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene. 2003;22:8924–30.CrossRefPubMed
Metadaten
Titel
The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients
verfasst von
T. Powrózek
R. Mlak
P. Krawczyk
I. Homa
M. Ciesielka
P. Kozioł
M. Prendecka
J. Milanowski
T. Małecka-Massalska
Publikationsdatum
01.02.2016
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 2/2016
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1343-6

Weitere Artikel der Ausgabe 2/2016

Clinical and Translational Oncology 2/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.